Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Current Assets (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Current Assets for 8 consecutive years, with $17.2 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 9.57% to $17.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.2 million through Dec 2025, up 9.57% year-over-year, with the annual reading at $17.4 million for FY2025, N/A changed from the prior year.
  • Current Assets for Q4 2025 was $17.2 million at Outlook Therapeutics, down from $17.4 million in the prior quarter.
  • The five-year high for Current Assets was $21.1 million in Q2 2025, with the low at $15.7 million in Q4 2024.